3D-MPLA in mRNA Vaccines: LNP Co-Delivery Strategies, Immune Mechanisms, and Research Advances

Introduction: The Evolving Role of 3D-MPLA in mRNA Vaccine Development

The development of mRNA vaccines has created new opportunities for vaccine research, but balancing antigen expression with effective immune activation remains an important challenge. Lipid nanoparticles (LNPs) protect mRNA and facilitate intracellular delivery, while adjuvants can help stimulate the innate immune responses required for effective adaptive immunity.

3D-MPLA, a monophosphoryl lipid A-related TLR4 agonist, is being investigated as an immune-stimulating component in vaccine formulations. When combined with mRNA delivery systems, it may help researchers control innate immune activation while maintaining antigen expression.

Interest is also growing in combining MPLA with CpG oligodeoxynucleotides (CpG-ODN), which activate Toll-like receptor 9 (TLR9). These approaches provide research opportunities for studying complementary immune signaling pathways and developing next-generation mRNA vaccine platforms.

1. Key Application Strategies for 3D-MPLA in mRNA Vaccines

Co-Delivering 3D-MPLA with Nucleoside-Modified mRNA

Nucleoside modifications, including pseudouridine (Ψ) and N1-methylpseudouridine (m1Ψ), are widely studied in mRNA vaccine development. Depending on the formulation, these modifications can improve mRNA translation and reduce certain unwanted innate immune responses.

However, reducing innate sensing of mRNA may also influence dendritic cell (DC) activation. This has encouraged researchers to investigate whether an adjuvant can provide additional immune stimulation without excessively suppressing antigen expression.

One strategy, discussed in research published by Verbeke and colleagues in 2017, involves combining nucleoside-modified mRNA with 3D-MPLA in lipid nanoparticle formulations. The objective is to support antigen production while providing a more controlled innate immune stimulus through TLR4 signaling.

For cancer mRNA vaccines, this approach may help promote antigen-specific T-cell responses. Its effectiveness depends on the adjuvant dose, formulation, delivery characteristics, and the balance between inflammatory signaling and mRNA translation. Further validation is required for each intended application.

Combining MPLA and CpG-ODN in LNP Formulations

Another research direction involves incorporating two adjuvants into the same LNP formulation. MPLA activates TLR4, while CpG-ODN can activate TLR9. Combining these components may allow researchers to investigate immune responses initiated through different cellular compartments.

A 2025 study by Pena Vaquero and colleagues in the International Journal of Biological Macromolecules examined an LNP-based formulation incorporating MPLA and CpG-ODN. The reported formulation strategy used a microfluidic process to combine components introduced through different phases.

Key areas of investigation included:

• Microfluidic formulation: Introducing CpG-ODN through the aqueous phase and MPLA through the lipid phase to facilitate nanoparticle formation.

• Particle characterization: Using techniques such as dynamic light scattering (DLS), nanoparticle tracking analysis (NTA), cryogenic transmission electron microscopy (cryo-TEM), and small-angle X-ray scattering (SAXS) to assess particle properties and structure.

• mRNA delivery: Evaluating whether the inclusion of adjuvants affects cellular uptake, intracellular delivery, and protein expression.

• Biocompatibility and immune activation: Examining cytotoxicity, hemolytic effects, and immune-related responses under experimental conditions.

• In vivo evaluation: Investigating biodistribution and the timing of innate immune responses following administration in experimental models.

These investigations are relevant to the design of multifunctional LNP systems. However, formulation performance, stability, safety, and immune activity must be assessed using the specific experimental data and conditions reported in each study.

2. How MPLA and CpG-ODN Influence Immune Responses

The rationale for combining MPLA and CpG-ODN lies in their ability to activate different Toll-like receptor pathways.

The actual response depends on the biological model, dose, formulation, and administration route. Combined TLR4 and TLR9 activation should not automatically be interpreted as synergistic, and stronger inflammatory responses do not necessarily indicate better vaccine performance. Researchers need to assess immune efficacy alongside tolerability and safety.

3. Current Research Directions

Cancer mRNA Vaccines

Cancer vaccines are an important area of mRNA research because they can be designed to encode tumor-associated or tumor-specific antigens. Researchers are exploring whether 3D-MPLA-containing LNPs can improve the interaction between antigen expression and dendritic cell activation.

The goal is to promote antigen-specific T-cell responses while avoiding excessive inflammatory signaling that could interfere with mRNA translation or compromise tolerability. These outcomes require validation in appropriate preclinical and clinical studies.

Infectious Disease Vaccine Platforms

MPLA-related adjuvants are also relevant to research on infectious disease vaccines. By studying the relationship between innate immune stimulation, antigen expression, and adaptive immune responses, researchers can evaluate formulation strategies for different vaccine targets.

Another emerging direction is the development of ionizable lipids with intrinsic immunostimulatory properties. Such materials may offer opportunities to combine delivery and immune activation within a single formulation, although their mechanisms and suitability must be established experimentally.

LNP Optimization and Adjuvant Evaluation

Adjuvants such as 3D-MPLA can serve as reference components when researchers compare the immune activity of different LNP formulations.

Studies may evaluate dendritic cell activation, T follicular helper (Tfh) cell responses, germinal center B-cell activity, and antigen-specific T-cell responses. These measurements help researchers understand whether an optimized delivery system provides sufficient immune stimulation or whether an additional adjuvant may be beneficial.

Future work will need to address formulation stability, component compatibility, dose selection, biodistribution, and safety, as well as the relationship between experimental immune markers and meaningful vaccine outcomes.

4. Future Opportunities for 3D-MPLA-Based Formulations

Several research priorities are likely to shape further development of MPLA-containing mRNA delivery systems:

1. Optimize adjuvant ratios: Investigate how the relative amounts of MPLA, CpG-ODN, and mRNA affect formulation characteristics and immune responses.

2. Evaluate alternative adjuvant combinations: Explore combinations with other innate immune agonists where a clear scientific rationale and acceptable safety profile exist.

3. Improve formulation consistency: Assess particle size distribution, encapsulation efficiency, storage stability, and batch-to-batch reproducibility.

4. Expand disease-specific evaluation: Investigate potential applications in infectious disease vaccines and personalized cancer vaccine research.

5. Study integrated delivery systems: Examine whether novel ionizable lipids can provide both efficient mRNA delivery and appropriate immunostimulatory activity.

These directions remain areas of research rather than guaranteed routes to clinical application. Progress will depend on reproducible experimental results, appropriate safety evaluation, and evidence supporting each intended use.

5. GC Biotech's MPLA-Related Research Products

GC Biotech provides a range of MPLA-related products for immunology and vaccine research. These materials cover different acylation structures and can support investigations into TLR4 signaling, structure–activity relationships, and adjuvant formulation development.

The products are associated with lipid A materials derived from Salmonella minnesota R595, according to the supplied product information. Researchers should consult the relevant product documentation to verify the exact chemical identity, structure, purity, handling requirements, and intended research use of each catalog item.

For projects involving mRNA-LNP co-delivery, product selection should be based on the research objective, the desired immune pathway, formulation compatibility, and the experimental model. Results obtained with one MPLA-related compound should not be assumed to apply equally to all acylation variants.

Conclusion

3D-MPLA and related monophosphoryl lipid A compounds are important research materials for investigating TLR4-mediated immune activation in vaccine development. Their combination with mRNA-loaded LNPs, including formulations that also contain CpG-ODN, offers opportunities to study the relationship between antigen expression, innate immune signaling, and adaptive immunity.

Further progress will require careful formulation optimization, reproducible characterization, and systematic evaluation of efficacy and safety. GC Biotech's MPLA-related product portfolio provides research options for scientists investigating adjuvant mechanisms, structure–activity relationships, and next-generation vaccine formulations.

https://en.jicangbio.com/application-and-research-progress-of-3d-mpla-in-mrna-vaccines.html

en.jicangbio.com
GC Biotech